J K Field|S W Duffy - JoVE Visualize

Showing results (291-300 of 301) with videos related to

Pageof 31

Sort By:

Lung Cancer (Amsterdam, Netherlands)|May 17, 2000

Allelic imbalance at the 5q14 locus is associated with decreased apoptotic rate in non-small cell lung carcinomas (NSCLCs). Possible synergistic effect with p53 gene alterations on apoptosisV G Gorgoulis, G Mariatos1, E N Manolis, et al.

British Journal of Cancer|December 25, 2013

Reduction in interval cancer rates following the introduction of two-view mammography in the UK breast screening programmeA Dibden, J Offman, D Parmar, et al.

Molecular Medicine (Cambridge, Mass.)|August 31, 2000

Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs)V G Gorgoulis, P Zacharatos, A Kotsinas, et al.

Health Technology Assessment (Winchester, England)|March 16, 2013

Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort studyS W Duffy, J Mackay, S Thomas, et al.

International Journal of Oncology|July 16, 2002

Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populationsJ K Field, C Brambilla, N Caporaso, et al.

Genomics|July 20, 1999

Envoplakin, a possible candidate gene for focal NEPPK/esophageal cancer (TOC): the integration of genetic and physical maps of the TOC region on 17q25J M Risk, C Ruhrberg, H Hennies, et al.

ESMO Open|February 5, 2026

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.

ESMO Open|June 4, 2024

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-RA R Filippi, J Bar, C Chouaid, et al.

The European Respiratory Journal|December 2, 2009

EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaborationJ K Field, T Liloglou, A Niaz, et al.

Nature Communications|August 22, 2019

Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoidsN Alcala, N Leblay, A A G Gabriel, et al.

Pageof 31

Showing results (291-300 of 301) with videos related to

Sort By:

Pageof 31

Lung Cancer (Amsterdam, Netherlands)|May 17, 2000

Allelic imbalance at the 5q14 locus is associated with decreased apoptotic rate in non-small cell lung carcinomas (NSCLCs). Possible synergistic effect with p53 gene alterations on apoptosisV G Gorgoulis, G Mariatos1, E N Manolis, et al.

British Journal of Cancer|December 25, 2013

Reduction in interval cancer rates following the introduction of two-view mammography in the UK breast screening programmeA Dibden, J Offman, D Parmar, et al.

Molecular Medicine (Cambridge, Mass.)|August 31, 2000

Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs)V G Gorgoulis, P Zacharatos, A Kotsinas, et al.

Health Technology Assessment (Winchester, England)|March 16, 2013

Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort studyS W Duffy, J Mackay, S Thomas, et al.

International Journal of Oncology|July 16, 2002

Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populationsJ K Field, C Brambilla, N Caporaso, et al.

Genomics|July 20, 1999

Envoplakin, a possible candidate gene for focal NEPPK/esophageal cancer (TOC): the integration of genetic and physical maps of the TOC region on 17q25J M Risk, C Ruhrberg, H Hennies, et al.

ESMO Open|February 5, 2026

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.

ESMO Open|June 4, 2024

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-RA R Filippi, J Bar, C Chouaid, et al.

The European Respiratory Journal|December 2, 2009

EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaborationJ K Field, T Liloglou, A Niaz, et al.

Nature Communications|August 22, 2019

Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoidsN Alcala, N Leblay, A A G Gabriel, et al.

Pageof 31